Teaming Up with your Doctor to

Improve Equity in Care for Multiple

Myeloma

Presented by:

Monique Hartley-Brown, MD, MMSc
Attending Physician, Jerome Lipper
Multiple Myeloma Center
Dana-Farber Cancer Institute
Associate Physician,
Brigham & Women's Hospital
Department of Medical Oncology
Amy Pierre, MSN, RN, ANP-BC Laura Ortiz-Ravick
Senior Clinical Director, Real World Director, Outreach and Health Promotion
Evidence Research Organization, The Leukemia & Lymphoma Society
Flatiron Health
Nurse Practitioner, Memorial Sloan
Kettering Cancer Center

This patient education program is supported by GlaxoSmithKline and by an educational grant from Janssen Biotech, Inc.,
administered by Janssen Scientific Affairs, LLC.
This activity is not certified for continuing education.
Speaker Disclosures

▪ Monique Hartley-Brown, MD, MMSc

− Advisory Role: GSK, BMS-Celgene, Sanofi, Pfizer,
Janssen, AstraZeneca

▪ Amy Pierre, MSN, RN, ANP-BC

− Employee: Flatiron Health
− Advisory Board: Pfizer
− Stock: Roche

▪ Laura Ortiz-Ravick
− No relevant personal financial relationships to disclose
2
Learning Objectives

▪ Discuss racial disparities in risk factors,

prevalence, treatment, and outcomes of
patients with myeloma
▪ Review approved and emerging treatments
for newly diagnosed and relapsed/refractory
myeloma, including expected side effects
▪ Discuss participation in clinical trials,
communication with the healthcare team,
and finding support and resources
3
Statement on Discussions on Race/Ethnicity

▪ The CancerCoachLive team recognizes that

participants in this activity are diverse in
representation including different races,
ethnicities, cultures, ages, and environments.
▪ For the purposes of our discussion on
race/ethnicity the following terms will be used:
− African Diaspora → African, African-American,
and/or Afro-Caribbean descent
− White → White (non-Hispanic) American

4
 AP

Multiple Myeloma (MM)

and Higher Prevalence
in the African Diaspora
Audience Polling Question

How would you describe the

stage of your disease?

A. Watch-and-wait
B. Newly diagnosed
C. First/second/etc., recurrence or relapse
D. In remission

6
Multiple Myeloma: An Overview

▪ MM is a cancer of the
plasma cells, a type of
blood cell found in your
bone marrow
▪ Plasma cells are a type of B
cell that make antibodies to
attack and kill germs in your
body
▪ When these cells become
cancerous, they begin to
grow and multiply out of
control

7
Risk Factors for MM
Risk factors for MM include:

Age Weight
Older people are Overweight people can
at higher risk be at higher risk

Gender Family History

Males are at A 1st degree relative with
higher risk MM increases your risk

Race Malignant Conditions

African-Americans Inflammatory conditions,
are at higher risk other hematologic
malignancies
8
MM in the African Diaspora
Did you know?
In comparison to a White population, African Diaspora populations…

Have a higher (2-3X) Are 2X as likely to

incidence of MGUS develop MM and 2X more
and SMM likely to die from it

Present with MM at a Have poorer outcomes

younger age despite stage of disease

9
 Barriers to Accessing Care in the
African Diaspora
▪ African Diaspora populations with MM are
more likely to experience:

Delays in Limited access

Delays in Sub-standard
diagnosis → to new
care compared Higher cost of
treatment treatments or
to White care
diagnosed at clinical trials
initiation patients
later stages (21% lower)

10
Removing Barriers to Accessing
Care
Barriers to care access can result in worse outcomes
for patients and increased mortality rates

▪ When care is equally ▪ Improved access to

provided for all patients, care leads to
research shows that
survival rates are: Better access to new
treatment options
− EQUAL among patients
aged 65+ years Better quality of life
for patients
− BETTER among younger
Black patients (less than 65 Better outcomes
years of age)

11
 MHB

New Options and

Emerging Therapies for
Newly Diagnosed MM
Choosing a Therapy for Newly
Diagnosed MM
▪ Your oncologist will take certain factors into consideration before
deciding on a treatment, such as: other conditions, disability and
frailty, transplant eligibility
▪ Treatment options could include combinations of up to three or
four drugs, given at either full dose or a reduced dose
▪ Typical first-line therapy includes:
1. Myeloma therapy
• Triplet Therapy = an immunomodulator, proteasome inhibitor, and a steroid

2. Bone-targeting therapy to prevent bone damage and strengthen

bones
3. Supportive care to ease symptoms and side effects of treatment
• Prophylactic medication to prevent infections or other complications

13
 Approved Treatment Options for Newly
Diagnosed MM
Standard of Care = Triplet Therapy
Antibodies are protective proteins produced by
your own immune system to fight against
antigens (foreign substances).

TYPE (CLASS) OF MEDICATION MEDICATIONS

Immunomodulator (IMiD) Pomalidomide,
(Activates immune system to destroy myeloma cells) lenalidomide

Proteasome inhibitor (PI) Carfilzomib, ixazomib,

(Blocks proteins that myeloma cells need to survive) bortezomib

Steroid Dexamethasone,
(Increases myeloma cell destruction in combination with other therapies) prednisone

Monoclonal antibody Daratumumab (IV) or

(Identify myeloma cell by specific markers on the myeloma cells, binding Daratumumab and
and destroying the myeloma cells) hyaluronidase-fihj (SC)

Chemotherapy Melphalan
(Therapy given in cycles to destroy myeloma cells)
14
 Transplant Eligibility Drives Treatment
Decisions: Talk to Your Doctor
A clinical trial should always be part of the initial treatment discussion

THERAPY COMBINATION RECOMMENDATION

Stem Cell Transplant Candidates
Bortezomib, lenalidomide, and dexamethasone Preferred regimen
Carfilzomib, lenalidomide, and dexamethasone Preferred regimen
(NCCN recommendation not FDA approved)
• Daratumumab, lenalidomide, bortezomib, and dexamethasone • Recommended regimen
Non-Stem Cell Transplant Candidates
Daratumumab, lenalidomide, and dexamethasone Preferred regimen
Bortezomib, lenalidomide, and dexamethasone Preferred regimen
• Daratumumab, bortezomib, melphalan, and prednisone • Recommended regimens
• Carfilzomib, lenalidomide, and dexamethasone
• Daratumumab, cyclophosphamide, bortezomib, and
dexamethasone
• Ixazomib, lenalidomide, and dexamethasone
Maintenance therapy includes: lenalidomide, bortezomib, daratumumab, ixazomib 15
Ongoing Clinical Trials for Newly
Diagnosed MM
Therapy Phase Clinical Trial Name Clinical Trial # Status
Belantamab mafodotin + 3 DREAMM-9: Newly NCT04091126 Recruiting
bortezomib + diagnosed myeloma
lenalidomide +
dexamethasone (VRd)
Ciltacabtagene-autoleucel 3 CARTITUDE-5: Newly NCT04923893 Ongoing
diagnosed myeloma, no
planned transplant
Teclistamab + 3 MajesTEC-7: Newly NCT05552222 Recruiting
daratumumab and diagnosed myeloma
lenalidomide (Tec-DR)
Idecabtagene vicleucel 3 KarMMA-4: High-risk, NCT04196491 Active, not
newly diagnosed recruiting
myeloma
Bortezomib + 3 EQUATE: Newly NCT04566328 Recruiting
Daratumumab + diagnosed myeloma
Hyaluronidase-fihj
dexamethasone (KRd) +
lenalidomide

16
Ongoing Clinical Trials for Newly
Diagnosed MM
Therapy Phase Clinical Trial Name Clinical Trial # Status
Teclistamab + 2 IFM 2021-01: Elderly NCT05572229 Not yet
daratumumab or patients with myeloma, recruiting
lenalidomide not transplant-eligible

Lenalidomide, ixazomib, 2 AFT-41: Newly NCT04009109 Recruiting

daratumumab, and diagnosed myeloma, not
dexamethasone transplant-eligible

Iberdomide, 2 IDEAL: Newly diagnosed NCT05392946 Recruiting

daratumumab + myeloma
bortezomib +
dexamethasone
Belantamab mafodotin + 1/2 BelaRd: Transplant- NCT04808037 Recruiting
lenalidomide + ineligible newly
dexamethasone diagnosed multiple
myeloma

17
Questions to Ask Your Team:
Discussing Treatment Options
▪ What are all of my treatment options? Do these options fit with
guidelines, or is my case different?
▪ How are my options affected by my age and other conditions that I
have?
▪ Will treatment be painful? Will I feel ill afterwards, and for how
long? What short- and long-term side effects should I expect?
▪ How often will I receive the treatment? Do I have need to prepare
in any way (e.g., stop medications, no food)
▪ Will treatment disrupt my daily activities? Should I have someone
there to help me?
▪ How would you know if the treatment is working?
▪ Could I stop treatment? What happens if I do that?
18
Common Side Effects of
Therapy
Side effects depend on the type of
treatment, but may include:
✓ Low blood counts ✓ Hair loss
✓ Pain ✓ Nausea/vomiting
✓ Fatigue ✓ Blood clots
✓ Memory loss ✓ Swelling (edema)
✓ Mental health changes ✓ Weight changes
✓ Constipation ✓ Diarrhea
✓ Peripheral neuropathy
19
Questions to Ask Your Team:
Discussing Side Effects
▪ What can I do about the side effects that I’m experiencing?
▪ Would side effects decrease if my treatment regimen is changed?
▪ Do side effects get better if the treatment is working? Will they
eventually go away on their own?
▪ If I need to take additional medication to ease side effects, will it
interfere with my myeloma treatment? Could it make me feel more
ill?
▪ If a side effect becomes serious or unbearable, what should I do
and who should I contact? If you are not available, should I go to
the emergency room?
▪ Are there any emotional or psychological coping resources
available to help me and/or those taking care of me?

20
 MHB

What to Do When
Relapse Occurs:
Treatment Options for
Relapsed/Refractory MM
Developing a Relapse/Refractory
Plan with Your Team
▪ A relapse occurs when cancer returns after a period of
improvement
− Can happen months to years after treatment
− Patients begin to experience return of symptoms or new ones
▪ Refractory cancer means that the cancer is not
responding to a certain medication
▪ It is normal and understandable to experience feelings of:

depression fear
anxiety uncertainty

22
Developing a Relapse/Refractory
Plan with Your Team
▪ You may have experienced some of
those feelings…
▪ You may be wondering if there are
other treatment options for you…

THERE IS HOPE!
▪ There are still treatment strategies to
use when your cancer relapses or is
resistant to certain treatments
▪ Your care team will work with you to
create a plan to prevent or reduce
the chances of the cancer returning
and to improve the outcomes of your
care journey

23
 Approved Treatment Options for
Relapsed/Refractory MM
TYPE (CLASS) OF MEDICATION MEDICATIONS
Immunomodulator (IMiD) (Activates immune system to destroy myeloma cells) Pomalidomide, Lenalidomide

Proteasome inhibitor (PI) (Blocks proteins that myeloma cells need to survive) Carfilzomib, Ixazomib, Bortezomib

Chemotherapy [>3 prior therapies] Bendamustine,

(Whole-body drug therapy given in cycles to destroy myeloma cells) Cyclophosphamide
CAR T-cell therapy [>4 prior therapies] (Treats cancer by turning your T-cells into Idecabtagene vicleucel,
more efficient cancer-fighting machines) Ciltacabtagene autoleucel
Monoclonal antibody (mAbs) Daratumumab (IV & SC),
(Identify myeloma cell by specific markers on the myeloma cells, binding and destroying the Elotuzumab, Isatuximab-irfc
myeloma cells)

Bi-specific antibody [>4 prior therapies] Teclistamab-cqyv

(A medication with 2 antibody binding domains that can attach to 2 antigens simultaneously)

Nuclear export inhibitor [1-3 prior therapies; >4 prior therapies] Selinexor
(Disrupts myeloma cell function)

Small molecule inhibitor [1-3 prior therapies] Venetoclax

(Penetrates myeloma cells to destroy them)

Steroid (Increases myeloma cell destruction in combination with other therapies) Dexamethasone

24
Therapy Combinations for Relapsed MM

Treatment Options for Patients with Relapsed Multiple Myeloma

Clinical trial (if eligible) – access to treatment not available outside of clinical trial
enrollment
Triplet combination therapy for previously treated myeloma – may include new
medications as well as medications that worked well for you in the past, discuss
combinations best for you with your treatment team
Stem cell transplant
Your team may also consider: CAR-T cell therapy and supportive care

YOU ARE THE PATIENT…

At all times, let your care team Shared decision-making
know if your treatment plan fits enhances your
your goals, preferences, values, treatment journey
and what matters to you
25
 Therapy Combinations for Refractory MM

1-3 previous therapies 3+ previous therapies

Bortezomib-refractory
• Daratumumab/len/dex
• Daratumumab/carfilzomib/dex
• Carfilzomib/len/dex
• Isatuximab/carfilzomib/dex
Lenalidomide-refractory
• Daratumumab/carfilzomib/dex
• Daratumumab/bortezomib/dex
• Isatuximab/carfilzomib/dex
After 1+ therapies IMiD+PI refractory
• Daratumumab/pomalidomide/dex
After 2+ therapies IMiD+PI refractory
• Isatuximab/pomalidomide/dex
After 2+ therapies IMiD+PI refractory,
with disease progression ≤ 60 days
• Pomalidomide/bortezomib/dex
• Bendamustine-based regimens
• High-dose/fractionated
cyclophosphamide
4+ previous therapies
• Teclistamab-cqyv
• Selinexor/dex
• Idecabtagene vicleucel
• Ciltacabtagene autoleucel

Clinical trial (if eligible) – access to treatment not available outside of clinical trial enrollment

Your care team will help you decide on options that

are available to you, even if your cancer is resistant
to some therapies or classes of medications
26
Len = lenalidomide; dex = dexamethasone
Audience Polling Question

What is your priority to

include as part of your
relapse plan?
A. New treatment options
B. More discussions with my care
team
C.New nutrition/exercise plan
D.Unsure

27
Questions to Ask Your Team:
Relapsed/Refractory MM
▪ The same questions that you would ask in the case of newly
diagnosed MM are applicable to relapsed/refractory MM
▪ In addition, you should ask your care team:
− Will my symptoms, age, and stage of cancer affect my treatment
options?
− How would you know which medication was not working so we can use
another one in its place?
− Will the new regimen be very different from the previous one? Will it
affect how I feel afterwards? Should I expect worse side effects than
before?
− What are the chances that cancer will return even if the treatment works
this time? What happens if treatment does not work this time – do I
have other options?
− How does my relapse plan change if I am already relapsed/refractory?
28
Patient Stories
Multiple Lines of Treatment
Adhering to Your Relapse Plan
▪ Your relapse plan may include recommendations to:

Maintain a healthy diet of fruits,

vegetables, lean proteins, and legumes

Stick to your treatment regimen and let

your care team know about side effects

Exercise regularly

Join support groups

30
Ongoing Clinical Trials for
Relapsed/Refractory MM
Therapy Phase Clinical Trial Name Clinical Trial # Status
Belantamab mafodotin as 3 DREAMM-8: NCT04484623 Recruiting
combination Relapsed/refractory myeloma
CC-92480 + carfilzomib + 3 SUCCESSOR-2: NCT05552976 Recruiting
dexamethasone (480Kd) vs Relapsed/refractory myeloma
carfilzomib + dexamethasone
(Kd)
Teclistamab alone vs 3 MajesTEC-9: NCT05572515 Recruiting
pomalidomide + bortezomib + Relapsed/refractory myeloma
dexamethasone or
carfilzomib + Kd
Teclistamab + daratumumab 3 MajesTEC-3: NCT05083169 Recruiting
Relapsed/refractory myeloma
Talquetamab + daratumumab 3 MonumenTAL-3: NCT05455320 Recruiting
+ pomalidomide or Relapsed/refractory myeloma
talquetamab + add’l agents
Talquetamab 1 MonumenTAL-1: NCT03399799 Recruiting
Relapsed/refractory myeloma

Therapies not yet approved by the FDA

31
 LOR

Accessing Clinical
Trials as Care and
Finding Support
Audience Polling Question LOR

Which one of the following factors

would most concern you when
considering participation in a clinical
trial?

A. Fear of the unknown

B. Concern of potential side effects

C. Potential associated costs

D. Transportation/lack of time or resources

E. Lack of trust in clinical research

33

Considering Clinical Trials
YOUR BEST TREATMENT OPTION MAY BE A CLINICAL TRIAL
▪ What are clinical trials?
− Research studies in which
people volunteer to help
evaluate a medical, surgical,
or behavioral intervention
▪ Why consider a clinical trial?
− A clinical trial may be the
best available treatment
option for you AND may help
others in the future
Access Clinical Trial Resource Hub Here
AP
▪ People of diverse
backgrounds are NEEDED
− Diversity in clinical trial
participation helps
researchers understand how
a drug works in people of
different ages, genders, and
races/ethnicities
− It ensures better equity in
cancer treatment options
for all patients
34
 LOR

Patient Stories
Clinical Trials
 AP
Participating in Clinical Trials:
What to Expect?
▪ Clinical trials can be a great option for receiving newer therapies
that are not yet approved by the FDA
▪ There are several steps to consider before enrolling in a clinical
trial, including:
− Eligibility for the study
− Testing that you may have to do before, during, and after
− What type of treatment will be given, side effects, and benefits/risks
− If you will need to travel/relocate and how costs will be covered
− Who will be on your care team to oversee your progress

Access Clinical Trial Resource Hub Here

36
When Should You Consider a
Clinical Trial?
Anytime If you are eligible for a trial, what may
happen?
• Your doctor may switch your current therapy to a
clinical trial with a novel agent
• You may decide the trial is not right for you at this
time → continue with current treatment plan
• Wait until current treatment is finished and see if
a trial is a viable option

(Newly Diagnosed or DISCUSS WITH YOUR TEAM

Relapsed/Refractory) What is the best option for you?
37
 A Guide to Discussing Clinical
Trials with Your Team

3. Ask questions!!!
Eligibility, locations, travel,
process, support.

2. Get matched! How? Talk to your

team or use a clinical trial finder.

Opportunities
Clinical Trial
E.g. LLS Clinical Trial Support Center

1. Gather information
about your cancer. Know
your: cancer type, stage, risk
stratification/ genetic
features, treatment history.

38
 Clinical Trial Resource Hub
Resources for Patients, Caregivers, Community

Access the Clinical

Trial Resource Hub
to learn more
CLICK HERE

Find Resources, such as:

• Ready with Knowledge:
A Cancer Clinical Trials Primer
• Is a Clinical Trial Right for Me?
A Patient-Provider Discussion Guide
• Set for Action:
Next Steps Clinical Trial Decision Tool
• Advocacy Support & Resources
https://www.cancercoachlive.com/cancer-clinical-trials-resource-hub/ 39
Audience Polling Question LOR

If you qualified for a clinical

trial, how likely are you to
participate in it?

A. Very likely
B. Likely
C. Somewhat likely
D. Not very likely
E. Not at all likely

40
Finding the Right Support and
Resources
▪ There are several support
groups that will connect
you to other people who
share similar experiences
as you

▪ Connecting with these

groups may be a great
part of your treatment
journey!

41
Patient Support and Resources

https://www.lls.org/support-resources https://blackdoctor.org/category/health
https://www.lls.org/treatment/types-treatment/clinical-trials -conditions/multiple-myeloma/

https://www.myeloma.org/support-groups https://themmrf.org/resources/find-a-support-group/

https://healthtree.org/myeloma https://www.cancersupportcommunity.org/cancer-support-helpline

42
Addressing the Needs of Myeloma Patients
Through LLS Free Resources
LLS Resources: www.LLS.org/Support

▪ Information Resource Center (IRC)– Highly

trained oncology social workers and nurses
assist patients with financial and social
challenges, disease, treatment and support
information
▪ Clinical Trial Support Center (CTSC) – Nurse
navigators help patients find clinical trials, and
address barriers associated with enrollment
▪ Nutrition Support – Registered dieticians
provide free nutrition education and one-on-one
consultations to patients/caregivers of all cancer
types
▪ Financial Support – Assistance programs
available to alleviate barriers blood cancer
patients face in accessing care
43
Addressing the Needs of Myeloma Patients
Through LLS Free Resources
▪ Provider Support – Resources for healthcare
providers, including booklets, podcasts and
CME/CE activities. https://www.lls.org/resources-
healthcare-professionals

▪ Education Resources – Includes disease-

specific booklets and fact sheets on treatment
options, side-effect management, caregiver
support workbooks and interactive web,
telephone, videos, and podcasts.
▪ Peer-to-Peer Support – connects patients
and caregivers with trained peer volunteer who
has gone through similar experience.
▪ LLS Online Community – Patients, survivors,
and caregivers share support, trusted
information and resources. Includes BIPOC
group for Black, Indigenous and people of
color.
44
Myeloma Link: Connecting Black Communities
to Information, Expert Care, and Support
▪ Patient education programs
▪ Church outreach through various
activities, including health-related
topics during services in Black
churches
▪ Community education programs in
collaboration with trusted partner
organizations
▪ Myeloma education programs for
community-based primary care
providers
▪ National and local media
outreach, including satellite media
tours and geo- and demo-targeted
search and social advertising

45
Q&A
with the experts

46
Thank you for participating today!

Visit CancerCoachLive.com and MedLive.com for Live and

Endured Patient Education Activities
References
• What is multiple myeloma? American Cancer Society.
https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html

• Risk factors for multiple myeloma. American Cancer Society.

https://www.cancer.org/cancer/multiple-myeloma/causes-risks-prevention/risk-factors.html

• Pierre A, Williams TH. African American patients with multiple myeloma: Optimizing care to
decrease racial disparities. Clin J Oncol Nurs. 2020;24(4):439-443.
• Kumar V, Alhaj-Moustafa M, Bojanini L, et al. Timeliness of initial therapy in multiple
myeloma: Trends and factors affecting patient care. JCO Oncol Pract. 2020;16(4):e341-
e349

• Fillmore NR, Yellapragada SV, Ifeorah C, et al. With equal access, African American
patients have superior survival compared to white patients with multiple myeloma: A VA
study. Blood. 2019;133(24):2615-2618

• Gormley N, Fashoyin-Aje L, Locke T, et al. Recommendations on eliminating racial

disparities in multiple myeloma therapies: A step toward achieving equity in healthcare.
Blood Cancer Discov. 2021;2(2):119-124

48
References
• Usmani S, Alonso AA, Quach H et al. DREAMM-9: Phase I study of belantamab mafodotin
plus standard of care in patients with transplant-ineligible newly diagnosed multiple
myeloma. Presented at: 63rd American Society of Hematology (ASH) Annual Meeting and
Exposition. Abstract 2738

• Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. A phase 1/2, dose and

schedule evaluation study to investigate the safety and clinical activity of belantamab
mafodotin administered in combination with lenalidomide and dexamethasone in
transplant-ineligible patients with newly diagnosed multiple myeloma. Presented at: 63rd
ASH Annual Meeting and Exposition. Abstract 2736

• ClinicalTrials.gov.A study of bortezomib, lenalidomide and dexamethasone(VRd)

followedbycilta-cel, a CAR- T therapy directed against BCMA versus VRd followed by
lenalidomide and dexamethasone (Rd) therapy in participants with newly diagnosed
multiple myeloma for whom ASCT is not planned as initial therapy (CARTITUDE-5).
Avaialable at: https://clinicaltrials.gov/ct2/show/NCT04923893. Accessed January 12, 2023

• GoldschmidtH, Mai EK, Nievergal lE, et al. Addition of isatuximab to lenalidomide,

bortezomiband dexamethasone as induction therapy for newly-diagnosed, transplant-
eligible multiple myeloma patients: The phase III GMMG-HD7 trial. Blood. 2021;138(Suppl
1):463.
49
References
• Pinheiro PS, Medina H, Callahan KE, et al. Cancer mortality among US blacks: Variability
between African Americans, Afro-Caribbeans, and Africans. Cancer Epidemiol.
2020;66:101709. doi: 10.1016/j.canep.2020.101709

• Ghandili S, Weisel KC, Bokemeyer C, Leypoldt LB. Current treatment approaches to

newly diagnosed multiple myeloma. Oncol Res Treat. 2021;44(12):690-699.
• ClinicalTrials.gov. Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in
Transplant-Ineligible Patients With Newly Diagnosed MM. Avaialable at:
https://clinicaltrials.gov/ct2/show/NCT04009109. Accessed January 12, 2023
• FDA. FDA approves idecabtagen evicleucel for multiple myeloma. Available at:
www.fda.gov/drugs/resources- information-approved-drugs/fda-approves-
idecabtagene-vicleucel-multiple-myeloma. Accessed January 12, 2023.
• Minnema MC, Krishnan AY, Berdeja JG, etal. Efficacy and safety of talquetamab ,a
G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody,
in patients with relapsed/refractory multiple myeloma (RRMM): Updated results
from MonumenTAL-1. J Clin Oncol. 2022;40(16):8015.
50
References
• NCCN Clinical Practice in Oncology Guidelines, Multiple Myeloma. Version 3.2023 – Dec
8, 2022. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

• NCCN Guidelines for Patients, Multiple Myeloma. 2023.

https://www.nccn.org/patients/guidelines/content/PDF/myeloma-patient.pdf

• Goldschmidt H et al. Navigating the treatment landscape in multiple myeloma: Which

combinations to use and when? Annals of Hematology. 2019;98:1-18
• https://blackdoctor.org/4-reasons-why-blacks-at-higher-risk-of-devloping-multiple-myeloma/

51